BGI Genomics
BGI Genomics
BGI Genomics is one of the world’s largest DNA sequencing service providers.
BGI Genomics, founded in August, 2008 and headquartered in Shenzhen, is a genomics R&D institution. The founder is Wang Jian. Listed on the SZSE on July 14, 2017, the company's major shareholders are BGI Genomics Co.,Ltd., Shenzhen Qianhai BGI Investment Enterprise (LP) and Shenzhen Heyu Gaolin Equity Investment Partnership (LP). Rivals that have direct and indirect competition with BGI Genomics include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
- All
- News
- Analysis
- Research
Briefing Mar 24, 2021 05:40 PM
· Healthcare
Cancer cell therapy company raised CNY 500 million in D round
Briefing Feb 01, 2021 02:41 PM
· Healthcare
Bh009 new drug project independently researched and developed by Beihai biological Co., Ltd. was approved by China's clinical trials
In depth
Briefing Jan 08, 2021 11:30 AM
· Healthcare
Xinyi biological completed 150 million round B financing, and Lilly Asia Fund led investment in Huachuang capital, hillhood venture capital and other follow-up investment
Briefing Dec 30, 2020 05:28 PM
· Healthcare
Another protein component special medical food was approved, and the total number of approved products increased to 57
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Dec 09, 2020 08:55 AM
Research
Consumer Staples, Real Estate, Consumer DiscretionaryTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Briefing Dec 28, 2020 02:44 PM
· Healthcare
BGI and Hanwei intelligent medical jointly launched mobile "two cancer" intelligent screening
Briefing Dec 02, 2020 11:21 AM
· Healthcare
Improving service quality and enabling industrial innovation!
Briefing Nov 17, 2020 08:04 PM
· Healthcare
Plan to raise $4 billion! Jingdong health runs IPO
Briefing Nov 11, 2020 10:42 AM
· Healthcare
Drug Innovator Asieris Nabs CNY 700 Million Series D
Briefing Nov 03, 2020 12:06 PM
· Healthcare
HaoYuan Chemexpress Files for IPO on the Star Market
Briefing Oct 16, 2020 04:24 PM
· Healthcare
Beijing Immunochina Pharmaceutical Closes Series C+ at CNY 100 Mn
Briefing Sep 28, 2020 08:25 PM
· Healthcare
Chinese Biotech Zai Laboratory Lands on HKEX after 3 Years' Listing on Nasdaq
Healthcare · Analysis
Open Source, Open Mind: Baidu and LinkingMed Help Doctors in Medical Images
A Chinese startup, based on Baidu’s deep-learning open-source platform PaddlePaddle, is providing CT screening service to a Hunan-based hospital, hoping to facilitate the diagnosis process.
Mar 05, 2020 11:41 AM
Briefing Sep 28, 2020 12:12 PM
· Healthcare
AI-Based Drug Research Platform XtalPi Closes Series C at USD 318.8 Mn
Briefing Sep 28, 2020 10:49 AM
· Healthcare
Broncus Biotech Closes Series C of Multi-Tens Millions US Dollars
Briefing Sep 23, 2020 11:37 AM
· Healthcare
Top-Tier CDMO Heyuan China Closes Series C at over CNY 300 Mn
Briefing Jul 02, 2020 02:13 PM
· Healthcare
BGI Genomics Plans to Raise CNY 2 billion to Expand Diagnosis Project
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
- More Room for the Medical Device Market to Grow in China
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.